Search Within

Michal F Segal

Formats
  1. Meeting Abstract (10)
  2. Journal Article (5)
Groups
  1. Department of Medicine (15)
  2. Gastrointestinal Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Center for Pancreatic Cancer Research (14)
  5. Biostatistics Service (9)
  6. Epidemiology and Biostatistics (9)

More Groups

People
  1. Marinela Capanu (9)
  2. David Kelsen (6)
  3. Ellen Hollywood (6)
  4. Leonard Saltz (6)
  5. Yelena Janjigian (6)
  6. Geoffrey Ku (5)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2014 (2)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer (2)
  3. Pancreas (2)
  4. Annals of Oncology (1)
  5. Clinical Cancer Research (1)
  6. Lancet Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Lippincott Williams & Wilkins (2)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Oxford University Press (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Lumish, M. A.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z. K.; Ku, G. Y.; Segal, N. H.; Won, E.; Maron, S. B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Lowery, M. A.; Capanu, M.; Stadler, Z. K.; Moore, M. J.; Dhani, N.; Kindler, H. L.; Estrella, H.; Maynard, H.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy-Lagunes, D.; Pietanza, M. C.; Segal, M.; Capanu, M.; Saltz, L.
    Pancreas (2014)

    Fulltext@MSK | Save
  • A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Pietanza, M. C.; Segal, M.; Capanu, M.; Saltz, L.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Yu, K. H.; Capanu, M.; Stadler, Z. K.; Epstein, A. S.; Golan, T.; Segal, A.; Segal, M.; Salo-Mullen, E. E.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save